Eduardo Benchimol Saad

Eduardo Benchimol Saad

Auto-generated profile, based on publicly available information

Eduardo Benchimol Saad

Electrophysiology and Pacing, Hospital Samaritano Botafogo , Rio de Janeiro

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2024 in EP Europace
Verified
Journal Article
Open access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P Gerstenfeld
Edward P Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo B Saad
Eduardo B Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
STSerge A Trines
Serge A Trines
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society .

8 April 2024 in Heart Rhythm
Verified
Journal Article
Open access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo B. Saad
Eduardo B. Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
EWElaine Y. Wan
Elaine Y. Wan
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society.

1 October 2011 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
ESEduardo B. Saad
Eduardo B. Saad
ADAndre D’Avila
Andre D’Avila
ICIeda P. Costa
Ieda P. Costa
AAArash Aryana
Arash Aryana
CSCharles Slater
Charles Slater
CPCarisi A. Polanczyk
Carisi A. Polanczyk
Background—: Long-term cessation of oral anticoagulation (OAC) after catheter ablation of atrial fibrillation (AF) has been deemed controversial. The safety of this management strategy in patients without recurrent AF and with historically elevated risks for thromboembolism remains largely unknown. In this study, we sought to evaluate the long-term results of OAC cessation after successful catheter ablation of AF. Methods and Results—: OAC and antiarrhythmic drugs (AADs) were discontinued irrespective of AF type or baseline CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack) risk score in 327 patients (mean age, 63±13 years; 79% men) with drug-refractory AF after catheter ablation (mean CHADS 2 score, 1.89±0.95; median, 2.0). Patients with a CHADS 2 score of 2 (45.4%) and 3 (23.2%) accounted for 68.8% of this cohort. In patients with a high risk of recurrence or prior thromboembolic complications, OAC was continued for up to 6 to 12 months postablation and antiplatelet therapy was administered to all patients who maintained sinus rhythm upon OAC interruption. After a follow-up of 46±17 months (range, 13–82 months), 82% remained AF free (off AADs). Significant predictors of late AF recurrence ( P 40 mm (HR, 3.52), CHADS 2 score ≥2 (HR, 1.81), and early recurrences (HR, 5.52). No symptomatic ischemic cerebrovascular events were detected during follow-up despite interruption of OAC in 298 (91%) patients and AADs in 293 (89%) patients. Conclusions—: No significant thromboembolic-related morbidity is observed when AADs and OAC are discontinued after successful catheter ablation of AF in patients with a CHADS 2 score ≤3 who are maintained on antiplatelet therapy during long-term follow-up.

13 April 2024 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo Saad
Eduardo Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
EWElaine Y. Wan
Elaine Y. Wan

6 October 2024 in Journal of Arrhythmia
Verified
Journal Article
Open access
STStylianos Tzeis
Stylianos Tzeis
EGEdward P. Gerstenfeld
Edward P. Gerstenfeld
JKJonathan Kalman
Jonathan Kalman
ESEduardo B. Saad
Eduardo B. Saad
Alireza Sepehri ShamlooAlireza Sepehri Shamloo
Alireza Sepehri Shamloo
EWElaine Y. Wan
Elaine Y. Wan
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence‐based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare professionals involved in catheter or surgical AF ablation. Mounting research evidence and technological advances have resulted in a rapidly changing landscape in the field of catheter and surgical AF ablation, thus stressing the need for regularly updated versions of this partnership which were issued in 2012 and 2017. Seven years after the last consensus, an updated document was considered necessary to define a contemporary framework for selection and management of patients considered for or undergoing catheter or surgical AF ablation. This consensus is a joint effort from collaborating cardiac electrophysiology societies, namely the European Heart Rhythm Association, the Heart Rhythm Society, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
FFFabio Fernandes
Fabio Fernandes
MSMarcus V. Simões
Marcus V. Simões
ECEdileide de Barros Correia
Edileide de Barros Correia
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
OCOtavio Rizzi Coelho-Filho
Otavio Rizzi Coelho-Filho
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...] 1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis